{"id":68018,"name":"BIOMERIEUX, INC.","slug":"biomerieux-inc","state":"UT","country":"United States of America","description":"Global in vitro diagnostics company.","totalSpending":170000,"filings":4,"yearlySpending":[{"year":2025,"income":170000}],"issues":["BUD","HCR","MED","MMM","TRD","TAX"],"firms":["ALSTON & BIRD LLP"],"lobbyists":["ALEXANDER GRAF","MARK RAYDER","EVAN COLLIER","JOYCE GRESKO","JOSEPH BODDICKER","JONATHAN JAGODA","JAMES PALUSKIEWICZ","MICHAEL PARK"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiot","H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiot","H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiot","H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiot","H.R.1, the One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiot"],"years":[2025]}